Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | TSPO | P30536 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879680 | 0.88 | THRA (0.35) | ESR1RARBTSHRTHRATHRB | |
| SCHEMBL10290777 | 0.88 | ESR1 (0.34) | ESR1RARBTSHRTHRATHRB | |
| SCHEMBL16302214 | 0.86 | ESR1 (0.35) | ESR1TSPORARBTHRATHRB | |
| SCHEMBL10290846 | 0.86 | TSHR (0.35) | TSPOTSHRLMNAALDH1A1 | |
| SCHEMBL850038 | 0.85 | TSPO (0.41) | TSPOTSHRLMNAALDH1A1 | |
| SCHEMBL13065129 | 0.83 | TSHR (0.35) | ESR1RARBTSHRTHRATHRB | |
| SCHEMBL13552298 | 0.82 | TSPO (0.37) | TSPOTSHRLMNAALDH1A1 | |
| SCHEMBL879677 | 0.82 | TSHR (0.39) | RARBTSHRLMNAPOLBALDH1A1 | |
| SCHEMBL847882 | 0.81 | TP53 (0.38) | TSPOTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL849896 | 0.81 | ALDH1A1 (0.34) | TSPOTSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | ESR1 2016/4885TSPO 2535/4885RARB 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.